ArticleCancer discovery2018
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05163106 (Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer), which is not on this map. Cited by 488 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
488citing papers in PubMed, 1 pooled it
22.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.
Who cites it
488 citing papers in PubMed, 1 synthesis or guideline pooled it, 756 citations in OpenAlex.
- CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates.Frontiers in immunology · 2026Pooled it
- Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.Journal for immunotherapy of cancer · 2026Trial
- Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer.Journal of experimental & clinical cancer research : CR · 2026Trial
- Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.ESMO open · 2026Trial
- Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.Nature communications · 2025Trial
- A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study.Cancer communications (London, England) · 2025Trial
- Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial.JNCI cancer spectrum · 2025Trial
- Trial
- Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I).JCO precision oncology · 2024Trial
- Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.Breast cancer research and treatment · 2023Trial
- Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).Journal for immunotherapy of cancer · 2023Trial
- Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications.The Journal of clinical investigation · 2026Review
- Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.Journal of clinical medicine · 2026Article
- CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.Targeted oncology · 2026Review
- Chemotherapy-induced cell cycle arrest is associated with increased claudin-18 isoform 2 expression and enhanced zolbetuximab-mediated cytotoxicity in gastric cancer.Journal of gastroenterology · 2026Article
- Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling.International journal of molecular sciences · 2026Review
- CDK4/6 Inhibitor-Induced Senescence in Cancer: Mechanisms and Therapeutic Implications.Cancers · 2026Review
- CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.Nature reviews. Drug discovery · 2026Review
428 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
47 authors at 1 institution in 1 country.
Jiehui Deng *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eric S Wang *Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
Russell W Jenkins *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shuai LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ruben DriesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kathleen YatesDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sandeep ChhabraDepartment of Cancer Biology, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
Wei HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hongye LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Amir R ArefDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Elena IvanovaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cloud P PaweletzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michaela BowdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Chensheng W ZhouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Grit S Herter-SprieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jessica A SorrentinoG1 Therapeutics, Research Triangle Park, North Carolina.
John E BisiG1 Therapeutics, Research Triangle Park, North Carolina.
Patrick H LizotteDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ashley A MerlinoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Max M QuinnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lauren E BufeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Annan YangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Yanxi ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hua ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Peng GaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ting ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Megan E CavanaughDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Amanda J RodeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eric HainesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Patrick J RobertsG1 Therapeutics, Research Triangle Park, North Carolina.
Jay C StrumG1 Therapeutics, Research Triangle Park, North Carolina.
William G RichardsDivision of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Jochen H LorchDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sareh ParangiDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Viswanath GundaDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Genevieve M BolandDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Raphael BuenoDivision of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Sangeetha PalakurthiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jerome RitzDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.
W Nicholas HainingDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Norman E SharplessThe Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Haribabu ArthanariDepartment of Cancer Biology, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
Geoffrey I ShapiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. kwok-kin.wong@nyumc.org Nathanael_Gray@dfci.harvard.edu dbarbie@partners.org.
Nathanael S GrayDepartment of Cancer Biology, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts. kwok-kin.wong@nyumc.org Nathanael_Gray@dfci.harvard.edu dbarbie@partners.org.
Kwok-Kin WongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. kwok-kin.wong@nyumc.org Nathanael_Gray@dfci.harvard.edu dbarbie@partners.org.
Dana-Farber Cancer Institute · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MTuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9MTransformed Esophageal Epithelial Cells and the Tumor MicroenvironmentP01CA098101 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RUSTGI, ANIL K · 2003 to 2023
$31.7MStructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI MEYERSON, MATTHEW L. · 2012 to 2021
$17.8MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MThe Role of p16INK4 in Mammalian AgingR01AG024379 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HE, SHENGHUI · 2004 to 2019
$4.6MDegrading therapeutically important kinases using small moleculesR01CA218278 · NCI · STANFORD UNIVERSITY · PI Eric Sebastian Fischer, NATHANAEL Schiander GRAY · 2019 to 2026
$4.6MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MIn vivo analysis of EGFR mutant driven lung cancers responses to radiation therapR01CA122794 · NCI · DANA-FARBER CANCER INST · PI WONG, KWOK KIN · 2006 to 2015
$2.8MIn vivo murine models of metastasis for therapeutic testingR01CA163896 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHARPLESS, NORMAN E, WONG, KWOK KIN · 2012 to 2016
$2.0MDevelopment and Application of Selective Covalent Cdk7 InhibitorsR01CA179483 · NCI · DANA-FARBER CANCER INST · PI GRAY, NATHANAEL SCHIANDER, MITSIADES, CONSTANTINE S. · 2014 to 2016
$1.5MNCI NIH HHS P01 CA098101NCI NIH HHS P01 CA120964NCI NIH HHS P01 CA154303NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA122794NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA163896NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA179483NCI NIH HHS R01 CA218278NCI NIH HHS T32 CA009172NIA NIH HHS R01 AG024379
Abstract
Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the efficacy of existing immunotherapies, we screened for small molecules capable of increasing the activity of T cells suppressed by PD-1. Here, we show that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) significantly enhances T-cell activation, contributing to antitumor effects
Indexed as
AnimalsAntineoplastic AgentsAntineoplastic Agents, ImmunologicalCell Line, TumorCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HumansLymphocyte ActivationLymphocytes, Tumor-InfiltratingMiceNeoplasmsProtein Kinase InhibitorsT-LymphocytesXenograft Model Antitumor AssaysAntineoplastic AgentsAntineoplastic Agents, ImmunologicalCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05163106ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.